Fig. 9.

In vivo antitumor effects of pCas9-sgLDHA/F3. (A) Tumor inoculation and dosing schedules are illustrated. Mice bearing B16F10 tumors were injected intratumorally with pCas9-sgLDHA/F3 on Day 7, 9 and 11, and with PD-L1 Ab on Day 13, 15 and 17. (B) Mean tumor volumes of various groups were measured (n = 5 per group). (C-F) Tumor volume changes of each mouse are presented for the untreated group (C), the PD-L1 Ab-treated group (D), the pCas9-sgLDHA/F3-treated group (E) and the PD-L1 Ab plus pCas9-sgLDHA/F3-treated group (F). (G) Tumor tissues of various groups were dissected at Day 17 after tumor inoculation. Scale bar: 1 cm. (H) Survival of mice was monitored after tumor inoculation at day 0. *P < 0.05; **P < 0.01; ***P < 0.001.